https://www.selleckchem.com/products/icg-001.html
he differential APOE allele effects on AD and comorbid pathologies. Thus, APOE genotype contributes to the heterogeneity in rate of clinical progression in AD. To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, in participants with neuromyelitis optica spectrum disorder (NMOSD). Adults (N = 23 with aquaporin-4 immunoglobulin G-seropositive NMOSD or -seronegative neuromyelitis op
Like
Comment
Share
